Michael M. Pham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael M. Pham has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Allison Rosenthal
Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ 85054, USA
1 shared publication Cynthia S. Crowson
Department of Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, United States
1 shared publication- David J. DiCaudo
Mayo Clinic Arizona Department of Dermatology, Scottsdale, Arizona, USA
1 shared publication Dora M. Lam-Himlin
Department of Laboratory Medicine and Pathology, Mayo Clinic—Arizona, Phoenix, AZ
1 shared publication- Fawad Aslam
Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA
1 shared publication Giovanni Orsolini
Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy
1 shared publication
Latest Publications
- Open Access
- 12 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (14) , 4940
Cutaneous Nodules and Inflammatory Arthritis: Two Illustrative Cases of Rare Mimics of Rheumatoid Arthritis
Background: Rheumatoid arthritis is a relatively common rheumatic disease that can present with inflammatory arthritis and subcutaneous nodules. Multicentric reticulohistiocytosis and fibroblastic rheumatism are rarer entities that also present with these features. Methods: Two cases, one of each of fibroblastic rheumatism and multicentric reticulohistiocytosis, are described highlighting characteristic clinical, radiographic, and histologic findings. A narrative review of the literature on these rarer conditions, compared with rheumatoid arthritis, is provided with a focus on articular and cutaneous findings, available information on disease presentations, and key contrasting features that can aid in diagnosis. Results: Radiographic erosion distribution and joint space narrowing, clinical nodule distribution and characteristics, and nodule histology can differ between these diseases. Conclusions: Multicentric reticulohistiocytosis and fibroblastic rheumatism should be considered in the evaluation of seronegative rheumatoid arthritis, especially in cases that do not respond predictably to standard therapies, and cutaneous nodule biopsy can aid in differentiating these three conditions.
- 12 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (14) , 4940
Open AccessCutaneous Nodules and Inflammatory Arthritis: Two Illustrative Cases of Rare Mimics of Rheumatoid Arthritis
Background: Rheumatoid arthritis is a relatively common rheumatic disease that can present with inflammatory arthritis and subcutaneous nodules. Multicentric reticulohistiocytosis and fibroblastic rheumatism are rarer entities that also present with these features. Methods: Two cases, one of each of fibroblastic rheumatism and multicentric reticulohistiocytosis, are described highlighting characteristic clinical, radiographic, and histologic findings. A narrative review of the literature on these rarer conditions, compared with rheumatoid arthritis, is provided with a focus on articular and cutaneous findings, available information on disease presentations, and key contrasting features that can aid in diagnosis. Results: Radiographic erosion distribution and joint space narrowing, clinical nodule distribution and characteristics, and nodule histology can differ between these diseases. Conclusions: Multicentric reticulohistiocytosis and fibroblastic rheumatism should be considered in the evaluation of seronegative rheumatoid arthritis, especially in cases that do not respond predictably to standard therapies, and cutaneous nodule biopsy can aid in differentiating these three conditions.
- Open Access
- 1 June 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (6) , e01746
New Diagnosis of Granulomatosis With Polyangiitis Presenting With Oral Ulcerations, Ileitis, and Hematochezia
Granulomatosis with polyangiitis (GPA) is a rare small vessel vasculitis that commonly presents with multiorgan involvement of the upper airways, lungs, and kidneys. We report a 55 year-old-man who presented with painful oral ulcers, diffuse joint pain, epistaxis, and intermittent maroon bowel movements. Infectious evaluation was unremarkable. Rheumatologic evaluation demonstrated elevated c-anti-neutrophil cytoplasmic antibody and proteinase 3 antibodies. Colonoscopy with terminal ileum biopsies demonstrated angiocentric inflammatory findings supportive of a diagnosis of GPA. This case was unusual in its presentation with predominately oral manifestations. A diagnosis of GPA should remain on the differential for patients with gastrointestinal bleeding, and these systemic symptoms require a high level of suspicion to lead to timely diagnosis.
- 1 June 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (6) , e01746
Open AccessNew Diagnosis of Granulomatosis With Polyangiitis Presenting With Oral Ulcerations, Ileitis, and Hematochezia
Granulomatosis with polyangiitis (GPA) is a rare small vessel vasculitis that commonly presents with multiorgan involvement of the upper airways, lungs, and kidneys. We report a 55 year-old-man who presented with painful oral ulcers, diffuse joint pain, epistaxis, and intermittent maroon bowel movements. Infectious evaluation was unremarkable. Rheumatologic evaluation demonstrated elevated c-anti-neutrophil cytoplasmic antibody and proteinase 3 antibodies. Colonoscopy with terminal ileum biopsies demonstrated angiocentric inflammatory findings supportive of a diagnosis of GPA. This case was unusual in its presentation with predominately oral manifestations. A diagnosis of GPA should remain on the differential for patients with gastrointestinal bleeding, and these systemic symptoms require a high level of suspicion to lead to timely diagnosis.
- 13 June 2022
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 122 (11) , 1948-1950
Is There Clinically Relevant Plasma Interference with ELISA Detection of APS Antibodies? Reproducibility of Real-World Paired Serum and Plasma Testing
The detection of antiphospholipid antibodies is a cornerstone requisite practice in the evaluation and diagnosis of antiphospholipid syndrome (APS). APS is commonly characterized by the detection of persisting antiphospholipid antibodies in the clinical context of thrombotic or obstetric manifestations. The 2006 Sydney Criteria outline clinical criteria and define anticardiolipin (aCL), anti-β-2 glycoprotein-1 (β2GP1), and the lupus anticoagulant in classifying definite APS.[1] Other antibodies, including anti-phosphatidylserine-prothrombin (aPSPT), have been identified and linked to APS though their clinical utility remains an area of uncertainty and subject to ongoing research. In the ELISA (enzyme-linked immunosorbent assay) detection of APS antibodies, the use of serum is thought preferable over plasma according to international consensus bodies and guidelines. The cited concerns include the dilution effects of the citrate anticoagulant needed in plasma sampling, possible matrix effects from fibrinogen, and potential for interference from platelets.[2] [3] [4] There are few studies suggesting that paired serum and plasma ELISA testing for antiphospholipid antibodies produce comparable quantitative values.[5] [6] [7] Further, there is a lack of replicating studies on a well-defined clinical population in a real-world clinical setting. Therefore, we sought to evaluate the reproducibility of ELISA detection of antiphospholipid antibodies in an all-comer clinical population undergoing medical evaluation for APS. A cross-section of all patients from our institution from June 2017 to December 2018 was identified undergoing serologic evaluations for suspected or previously diagnosed APS. The cohort underwent serum tests for immunoglobulin G and immunoglobulin M isotypes of aCL and β2GP1 which are recognized in the current 2006 Sydney APS classification criteria. Serologic testing used commercially available ELISA assays (QUANTA Lite, Inova Diagnostics, San Diego, California, United States) in a CLIA (Clinical Laboratory Improvement Amendments)-accredited medical laboratory. The same ELISA tests were repeated once from the same patient on the same day, platelet-poor citrated plasma. aPS-PT antibodies, which are not a part of current Sydney APS classification criteria, were also found to be tested in a small minority of patients and thus presented opportunity for repeat testing by plasma (QUANTA Lite, Inova Diagnostics, San Diego, California, United States). Plasma samples were stored at −80°C and tested within 3 weeks. Quantitative antibody levels were determined for each isotype without citrate volume correction and then stratified into the following reference value intervals for aCL and β2GP1: negative (<15.0 GPL/MPL or U/mL), weakly positive (15.0–39.9), or positive (≥40.0). For aPS-PT, the following reference value intervals were used: negative (≤30 U), borderline (30.1–39.9), or positive (≥40.0). Patient demographics and clinical characteristics were summarized using descriptive statistics (medians, percentages, etc.). Paired differences of antibody levels were compared using Wilcoxon paired signed-rank tests. Inter-sample reliability of resulted reference value intervals was compared using kappa coefficients. Analyses were performed using SAS version 9.4 (SAS Institute, Cary, North Carolina, United States). Proportion of those with autoimmune diseases were enumerated as determined by the related specialty physician. Particularly, patients diagnosed with APS met 2006 Sydney Criteria (revised 1999 Sapporo Criteria) and systemic lupus erythematosus (SLE) met 2012 SLICC (Systemic Lupus International Collaborating Clinics) criteria. One hundred fifty patients were identified for study with 134 aCL, 110 β2GP1, and 7 aPS-PT unique serum samples eligible for subsequent paired plasma testing. The cohort mean age was approximately 49 ± 17 years. Approximately 69% were female and 87% were white. Approximately 51% had one or more autoimmune condition. Notably, 21% had APS which included both newly diagnosed disease related to testing within the study's time frame and previously established disease. Approximately 13% met the criteria for SLE. As shown in [Table 1], median differences between serum and plasma were 0.0 units across all isotypes tested. There was a tendency for serum quantitative levels to have slightly higher values than plasma, and the differences were technically statistically significant. However, the mean differences were small and ranged within 2.1 units. There was strong inter-sample agreement in resulted laboratory reference interval categories with kappa coefficients ranging from 0.80 to 1.00. To our knowledge, we present the largest study examining the reproducibility of antiphospholipid antibody detection on paired serum and plasma samples in a real-world, all-comer clinical setting. The study was able to detect small differences between serum and plasma antiphospholipid antibody levels. There was a tendency for antibody levels from serum to be of slightly higher value when compared with plasma. The small differences detected may very well reflect previously cited concerns of citrate dilution and matrix effects. These effects, singly or in combination, would have a negative bias and underestimate the true result. However, the quantitative differences between the paired samples are notably small at no more than 2.1 units and are likely not of significant clinical relevance in the medical practice setting ultimately. This notion is corroborated by the strong inter-sample agreement between serum and plasma in the resulting reference intervals stratifying into negative, weakly positive, and positive. Strengths of this study includes the large sample size which has aided in detection of very small differences. Compared with prior studies, this study's use of real-world clinical patients with...
- 13 June 2022
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 122 (11) , 1948-1950
Is There Clinically Relevant Plasma Interference with ELISA Detection of APS Antibodies? Reproducibility of Real-World Paired Serum and Plasma Testing
The detection of antiphospholipid antibodies is a cornerstone requisite practice in the evaluation and diagnosis of antiphospholipid syndrome (APS). APS is commonly characterized by the detection of persisting antiphospholipid antibodies in the clinical context of thrombotic or obstetric manifestations. The 2006 Sydney Criteria outline clinical criteria and define anticardiolipin (aCL), anti-β-2 glycoprotein-1 (β2GP1), and the lupus anticoagulant in classifying definite APS.[1] Other antibodies, including anti-phosphatidylserine-prothrombin (aPSPT), have been identified and linked to APS though their clinical utility remains an area of uncertainty and subject to ongoing research. In the ELISA (enzyme-linked immunosorbent assay) detection of APS antibodies, the use of serum is thought preferable over plasma according to international consensus bodies and guidelines. The cited concerns include the dilution effects of the citrate anticoagulant needed in plasma sampling, possible matrix effects from fibrinogen, and potential for interference from platelets.[2] [3] [4] There are few studies suggesting that paired serum and plasma ELISA testing for antiphospholipid antibodies produce comparable quantitative values.[5] [6] [7] Further, there is a lack of replicating studies on a well-defined clinical population in a real-world clinical setting. Therefore, we sought to evaluate the reproducibility of ELISA detection of antiphospholipid antibodies in an all-comer clinical population undergoing medical evaluation for APS. A cross-section of all patients from our institution from June 2017 to December 2018 was identified undergoing serologic evaluations for suspected or previously diagnosed APS. The cohort underwent serum tests for immunoglobulin G and immunoglobulin M isotypes of aCL and β2GP1 which are recognized in the current 2006 Sydney APS classification criteria. Serologic testing used commercially available ELISA assays (QUANTA Lite, Inova Diagnostics, San Diego, California, United States) in a CLIA (Clinical Laboratory Improvement Amendments)-accredited medical laboratory. The same ELISA tests were repeated once from the same patient on the same day, platelet-poor citrated plasma. aPS-PT antibodies, which are not a part of current Sydney APS classification criteria, were also found to be tested in a small minority of patients and thus presented opportunity for repeat testing by plasma (QUANTA Lite, Inova Diagnostics, San Diego, California, United States). Plasma samples were stored at −80°C and tested within 3 weeks. Quantitative antibody levels were determined for each isotype without citrate volume correction and then stratified into the following reference value intervals for aCL and β2GP1: negative (<15.0 GPL/MPL or U/mL), weakly positive (15.0–39.9), or positive (≥40.0). For aPS-PT, the following reference value intervals were used: negative (≤30 U), borderline (30.1–39.9), or positive (≥40.0). Patient demographics and clinical characteristics were summarized using descriptive statistics (medians, percentages, etc.). Paired differences of antibody levels were compared using Wilcoxon paired signed-rank tests. Inter-sample reliability of resulted reference value intervals was compared using kappa coefficients. Analyses were performed using SAS version 9.4 (SAS Institute, Cary, North Carolina, United States). Proportion of those with autoimmune diseases were enumerated as determined by the related specialty physician. Particularly, patients diagnosed with APS met 2006 Sydney Criteria (revised 1999 Sapporo Criteria) and systemic lupus erythematosus (SLE) met 2012 SLICC (Systemic Lupus International Collaborating Clinics) criteria. One hundred fifty patients were identified for study with 134 aCL, 110 β2GP1, and 7 aPS-PT unique serum samples eligible for subsequent paired plasma testing. The cohort mean age was approximately 49 ± 17 years. Approximately 69% were female and 87% were white. Approximately 51% had one or more autoimmune condition. Notably, 21% had APS which included both newly diagnosed disease related to testing within the study's time frame and previously established disease. Approximately 13% met the criteria for SLE. As shown in [Table 1], median differences between serum and plasma were 0.0 units across all isotypes tested. There was a tendency for serum quantitative levels to have slightly higher values than plasma, and the differences were technically statistically significant. However, the mean differences were small and ranged within 2.1 units. There was strong inter-sample agreement in resulted laboratory reference interval categories with kappa coefficients ranging from 0.80 to 1.00. To our knowledge, we present the largest study examining the reproducibility of antiphospholipid antibody detection on paired serum and plasma samples in a real-world, all-comer clinical setting. The study was able to detect small differences between serum and plasma antiphospholipid antibody levels. There was a tendency for antibody levels from serum to be of slightly higher value when compared with plasma. The small differences detected may very well reflect previously cited concerns of citrate dilution and matrix effects. These effects, singly or in combination, would have a negative bias and underestimate the true result. However, the quantitative differences between the paired samples are notably small at no more than 2.1 units and are likely not of significant clinical relevance in the medical practice setting ultimately. This notion is corroborated by the strong inter-sample agreement between serum and plasma in the resulting reference intervals stratifying into negative, weakly positive, and positive. Strengths of this study includes the large sample size which has aided in detection of very small differences. Compared with prior studies, this study's use of real-world clinical patients with...
- Open Access
- 18 February 2017
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 11 (1) , 45
Classical Hodgkin lymphoma masquerading as chronic recurrent multifocal osteomyelitis: a case report
Hodgkin lymphoma is a hematologic malignancy usually confined to lymphatic structures and commonly associated with constitutional symptoms. Bony involvement and musculoskeletal symptoms are uncommon and typically seen in advanced disease. In this case, we report an unusual presentation of classical Hodgkin lymphoma and highlight diagnostic challenges leading to the misdiagnosis and treatment as chronic recurrent multifocal osteomyelitis. A 38-year-old white man presented with lower extremity musculoskeletal pain. Imaging studies revealed multifocal lytic and sclerotic osseous axial lesions. Multiple core needle bone marrow and excisional lymph node biopsies were non-diagnostic. Having met the criteria, a tentative diagnosis of chronic recurrent multifocal osteomyelitis was given. He was treated with non-steroidal anti-inflammatory medications with partial clinical response but had persistent symptoms. A second medical opinion was pursued. An open bone marrow biopsy was performed and yielded a diagnosis of classical Hodgkin lymphoma after 13 months of diagnostic uncertainty. A chemotherapy regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine was instituted with complete symptomatic and radiologic response. This case illustrates diagnostic difficulties of a musculoskeletal presentation of Hodgkin lymphoma, challenges of non-diagnostic bone marrow and lymph node biopsies, and resultant diagnostic delays in delivering a potentially curative therapy. Had the additional open bone marrow biopsy not been performed, the diagnosis and treatment of Hodgkin lymphoma would have been missed.
- 18 February 2017
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 11 (1) , 45
Open AccessClassical Hodgkin lymphoma masquerading as chronic recurrent multifocal osteomyelitis: a case report
Hodgkin lymphoma is a hematologic malignancy usually confined to lymphatic structures and commonly associated with constitutional symptoms. Bony involvement and musculoskeletal symptoms are uncommon and typically seen in advanced disease. In this case, we report an unusual presentation of classical Hodgkin lymphoma and highlight diagnostic challenges leading to the misdiagnosis and treatment as chronic recurrent multifocal osteomyelitis. A 38-year-old white man presented with lower extremity musculoskeletal pain. Imaging studies revealed multifocal lytic and sclerotic osseous axial lesions. Multiple core needle bone marrow and excisional lymph node biopsies were non-diagnostic. Having met the criteria, a tentative diagnosis of chronic recurrent multifocal osteomyelitis was given. He was treated with non-steroidal anti-inflammatory medications with partial clinical response but had persistent symptoms. A second medical opinion was pursued. An open bone marrow biopsy was performed and yielded a diagnosis of classical Hodgkin lymphoma after 13 months of diagnostic uncertainty. A chemotherapy regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine was instituted with complete symptomatic and radiologic response. This case illustrates diagnostic difficulties of a musculoskeletal presentation of Hodgkin lymphoma, challenges of non-diagnostic bone marrow and lymph node biopsies, and resultant diagnostic delays in delivering a potentially curative therapy. Had the additional open bone marrow biopsy not been performed, the diagnosis and treatment of Hodgkin lymphoma would have been missed.